Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes

Drug Metabolism and Disposition

Volumn 32, Issue 11, 2004, Pages 1311-1316

  Lam, Justine L ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DRUG METABOLITE; ELACRIDAR; RIFAMPICIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; INCUBATION TIME; LIVER CELL; LIVER MICROSOME; MALE; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 6944219986     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.11.1311     Document Type: Article

References (35)

1. Allen JD and Schinkel AH (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1:427-434.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
3. Annaert PP, Turncliff RZ, Booth CL, Thakker DR, and Brouwer KL (2001) P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277-1283.
4. Antman EM and Smith TW (1985) Digitalis toxicity. Annu Rev Med 36:357-367.
5. Bayliss MK, Bell JA, Jenner WN, Park GR, and Wilson K (1999) Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29:253-268.
6. Benet LZ, Cummins CL, and Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393-398.
7. Cui Y, Konig J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
8. Cummins CL, Jacobsen W, and Benet LZ (2002a) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
9. Cummins CL, Jacobsen W, Christians U, and Benet LZ (2004) CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 308:143-155.
10. Cummins CL, Mangravite LM, and Benet LZ (2001) Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1 and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res (NY) 18:1102-1109.
11. Cummins CL, Salphati L, Reid MJ, and Benet LZ (2003) In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 305:306-314.
12. Cummins CL, Wu CY, and Benet LZ (2002b) Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72:474-489.
13. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
14. Harrison LI and Gibaldi M (1976) Pharmacokinetics of digoxin in the rat. Drug Metab Dispos 4:88-93.
15. Heller M (1990) Cardiac glycosides. New/old ideas about old drugs. Biochem Pharmacol 40:919-925.
16. Hinderling PH (1984) Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood. J Pharm Sci 73:1042-1053.
17. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
18. Lan LB, Dalton JT, and Schuetz EG (2000) Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58:863-869.
19. Lau YY, Wu CY, Okochi H, and Benet LZ (2004) Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308:1040-1045.
20. Li C, Benet LZ, and Grillo MP (2002) Enantioselective covalent binding of 2-phenylpropionic acid to protein in vitro in rat hepatocytes. Chem Res Toxicol 15:1480-1487.
21. Luo FR, Paranjpe PV, Guo A, Rubin E, and Sinko P (2002) Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT and MRP1. Drug Metab Dispos 30:763-770.
22. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
23. Noe B, Hagenbuch B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
24. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification and properties. J Biol Chem 239:2379-2385.
25. Renes J, de Vries EG, Jansen PL, and Muller M (2000) The (patho)physiological functions of the MRP family. Drug Resist Updat 3:289-302.
26. Salphati L and Benet LZ (1998) Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308-313.
27. Salphati L and Benet LZ (1999) Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica 29:171-185.
28. Savolainen J, Edwards JE, Morgan ME, McNamara PJ, and Anderson BD (2002) Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos 30:479-482.
29. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29-83.
30. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
31. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat oatp1 (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res (NY) 19:147-153.
32. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, and Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
33. Wu CY and Benet LZ (2003) Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine and GG918. Drug Metab Dispos 31:1292-1295.
34. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, and Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913-921.
35. Zong J and Pollack GM (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther 306:556-562.